• 1
    Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. July 31, 2012; pp 1235. Available at: Accessed 24 January 2013.
  • 2
    European AIDS Clinical Society Guidelines (EACS). Version 6.1, November 2012. Available at: Accessed 24 January 2013.
  • 3
    Tubiana R , Le Chenadec J , Rouzioux C , Mandelbrot L , Hamrene K , Dollfus C , et al. Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis 2010;50:58596.
  • 4
    Sturt AS , Dokubo EK , Sint TT . Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst Rev 2010;CD008440.
  • 5
    Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 Jan 1989 - 31 January 2012. Wilmington, NC: Registry Coordinating Center; 2012. Available at: Accessed 2 July 2012.
  • 6
    Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990–2007. AIDS 2009;23:51924.
  • 7
    Brogly SB, Abzug MJ, Watts DH, Cunningham CK, Williams PL, Oleske J, et al. Birth defects among children born to human immunodeficiency virus-infected women: paediatric AIDS clinical trials protocols 219 and 219C. Pediatr Infect Dis J 2010;29:7217.
  • 8
    Joao EC, Calvet GA, Krauss MR, Freimanis Hance L, Ortiz J, Ivalo SA, et al. Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study. J Acquir Immune Defic Syndr 2010;53:17685.
  • 9
    Watts DH, Huang S, Culnane M, Kaiser KA, Scheuerle A, Mofenson L, et al. Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. J Perinat Med 2011;39:16370.
  • 10
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents. Department of Health and Human Services. March 27, 2012; 1-240. Available at: Accessed 24 January 2013.
  • 11
    Loutfy M, Raboud J, Wong J, Yudin M, Diong C, Blitz S, et al. High prevalence of unintended pregnancies in HIV-positive women of reproductive age in Ontario, Canada: a retrospective study. HIV Med 2012;13:10717.
  • 12
    Floridia M, Ravizza M, Tamburrini E, Anzidei G, Tibaldi C, Maccabruni A, et al. Diagnosis of HIV infection in pregnancy: data from a national cohort of pregnant women with HIV in Italy. Epidemiol Infect 2006;134:11207.
  • 13
    Floridia M, Tamburrini E, Ravizza M, Anzidei G, Tibaldi C, Bucceri A, et al. Antiretroviral therapy at conception in pregnant women with HIV in Italy: wide range of variability and frequent exposure to contraindicated drugs. Antivir Ther 2006;11:9416.
  • 14
    Scheuerle A, Tilson H. Birth defect classification by organ system: a novel approach to heighten teratogenic signalling in a pregnancy registry. Pharmacoepidemiol Drug Saf 2002;11:46575.
  • 15
    Bertino E, Spada E, Occhi L, Coscia A, Giuliani F, Gagliardi L, et al. Neonatal anthropometric charts: the Italian neonatal study compared with other European studies. J Pediatr Gastroenterol Nutr 2010;51:35361.
  • 16
    Girardi E, Vanacore P, Costa F, Solmone M, Angeletti C, Capobianchi MR, et al. Trends in HIV prevalence among pregnant women in Italy, 1994–2002. J Acquir Immune Defic Syndr 2006;41:3614.
  • 17
    Watts DH, Li D, Handelsman E, Tilson H, Paul M, Foca M, et al. Assessment of birth defects according to maternal therapy among infants in the Women and Infants Transmission Study. J Acquir Immune Defic Syndr 2007;44:299305.
  • 18
    Patel D, Thorne C, Fiore S, Newell ML, European Collaborative Study. Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women? J Acquir Immune Defic Syndr 2005;40:1168.
  • 19
    Knapp KM, Brogly SB, Muenz DG, Spiegel HM, Conway DH, Scott GB, et al. Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr Infect Dis J 2012;31:16470.
  • 20
    Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2011;25:23014.
  • 21
    Nightingale SL. From the food and drug administration. JAMA 1998;280:1472.
  • 22
    De Santis M, Carducci B, De Santis L, Cavaliere AF, Straface G. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 2002;162:355.
  • 23
    Saitoh A, Hull AD, Franklin P, Spector SA. Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol 2005;25:5556.
  • 24
    Heidari S, Mofenson L, Cotton MF, Marlink R, Cahn P, Katabira E. Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children. J Acquir Immune Defic Syndr 2011;57:2906.